EYA2 and prostate cancer: In addition, the Cancer Genome Atlas (TCGA) prostate cohort revealed that expression of Eya2 was significantly higher in prostate cancers with higher Gleason scores (Kruskal-Wallis H test, p<0.0001, Figure 1(f)), higher T stage (Kruskal-Wallis H test, p<0.0001, Figure 1(g)), and positive nodal metastasis (Mann-Whitney U test, p=0.0095, Figure 1(h))(Figures 1(f)–1(h)).